Make an Appointment

Ask a Question
Refer a Patient

1.877.CALL NJH
(877.225.5654)

PANTHER-IPF: Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People with Idiopathic Pulmonary Fibrosis

Trial Location:
Main Campus, Denver, CO
Trial Objective:

To assess the safety and efficacy of N-acetylcysteine (NAC) and the combination of prednisone, azathioprine, and NAC in subjects with newly diagnosed idiopathic pulmonary fibrosis

Patient Groups:
390 patients will enroll in the study from 22 centers in the United States.

  • 130 patients will receive will receive a placebo.
  • 130 patients will receive will receive a NAC only.
  • 130 patients will receive will receive a combination therapy of prednisone, azathioprine, and NAC

Visits:

  • Approximately  8 study visits over 13 months
  • Screening visit to determine eligibility
  • Study visits 4 weeks and every 15 weeks after enrollment visit
  • Post treatment safety follow-up, up to 28 days after treatment
Compensation:

Not Provided

Who Can Participate:

  • Male or female patients between 35 and 80 years of age
  • Diagnosis of IPF in the 48 months before study entry
Enrollment:

Active Clinical Trials Closed to Recruitment